MorphoSys AG
XETRA:MOR

Watchlist Manager
MorphoSys AG Logo
MorphoSys AG
XETRA:MOR
Watchlist
Price: 67.25 EUR 0.37% Market Closed
Market Cap: 2.5B EUR

Gross Margin
MorphoSys AG

83.9%
Current
82%
Average
63.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
83.9%
=
Gross Profit
170.7m
/
Revenue
203.5m

Gross Margin Across Competitors

No Stocks Found

MorphoSys AG
Glance View

Market Cap
2.5B EUR
Industry
Biotechnology

MorphoSys AG emerged from the vibrant biotechnology landscape of Munich, Germany, in 1992. It was founded on the innovative idea of harnessing antibodies as a means to combat diseases. With a precision-driven approach to drug development, MorphoSys primarily concentrates on creating and bringing to market therapeutic agents for cancer and inflammatory disorders. Taking center stage is their proprietary technology platform that enables the discovery of monoclonal antibodies, pivotal in the fight against these daunting ailments. This platform not only serves their internal pipeline but also provides a significant source of revenue through collaborations and licensing agreements with major pharmaceutical giants, enabling MorphoSys to strike timely alliances that bolster both innovation and profitability. Central to MorphoSys's business model is its dual focus: advancing its own pipeline of antibody-based therapeutics while simultaneously offering its technological platforms to partners. This symbiosis allows the company to generate revenue through milestone payments and royalties as partnered drugs advance through clinical trials and into the market. A key asset in its lineup is Monjuvi, a groundbreaking treatment for lymphoma, which underscores the firm's capability to evolve from tech-driven operations to delivering market-ready solutions. As markets grow increasingly competitive, MorphoSys's strategic prowess lies in balancing its R&D investments with collaborative ventures, ensuring a steady revenue stream and a robust presence in the biopharmaceutical realm.

MOR Intrinsic Value
Not Available
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
83.9%
=
Gross Profit
170.7m
/
Revenue
203.5m
What is the Gross Margin of MorphoSys AG?

Based on MorphoSys AG's most recent financial statements, the company has Gross Margin of 83.9%.

Back to Top